Skip to main content
NameEmailPhD ProgramResearch InterestPublications
Morris, John
WEBSITE
EMAIL
PUBLICATIONS

PHD PROGRAM
Pharmacology

RESEARCH INTEREST
Cancer Biology, Developmental Biology, Genetics, Genomics, Metabolism

The Morris lab leverages flexible mouse models of hard to treat cancers of the pancreas and liver to identify how cancer drivers perturb evolutionarily selected developmental programs and how such programs may be re-normalized. We focus on (1) the relationship between tumor suppressor pathways and the epigenetic determinants of cell plasticity, (2) evolutionary routes unleashed by specific tumor suppressor loss, and (3) how diversification at both the epigenetic and genomic level contribute to cancer development and therapeutic response.

Smith, Keriayn
WEBSITE
EMAIL
PUBLICATIONS

PHD PROGRAM
Genetics & Molecular Biology

RESEARCH INTEREST
Cancer Biology, Cell Biology, Genetics, Genomics, Molecular Biology

We are interested in elucidating context-specific functions of products from single long noncoding RNA (lncRNA) loci. Since lncRNAs have been implicated in many cellular processes, it is critical to delineate specific roles for each lncRNA. Moreover, as they are increasingly associated with diseases including developmental disorders, degenerative diseases, and cancers, defining their functions will be an important precursor to their use as diagnostics and therapeutics. We specialize in adopting -omics approaches including genomics, transcriptomics and proteomics, combined with single molecule methods to study the intermolecular interactions – RNA-protein, RNA-RNA and RNA-chromatin that lncRNAs use to execute their functions in normal stem cells and cancer.

Coleman, Leon
WEBSITE
EMAIL
PUBLICATIONS

PHD PROGRAM
Neuroscience, Pharmacology

RESEARCH INTEREST
Behavior, Cancer Biology, Cell Signaling, Drug Discovery, Immunology, Molecular Biology, Neurobiology, Pharmacology, Translational Medicine

The overriding goal of Dr. Coleman’s work is to identify novel treatments for alcohol use disorders (AUD) and associated peripheral disease pathologies. Currently, this includes: the role of neuroimmune Signaling in AUD pathology, the role of alcohol-associated immune dysfunction in associated disease states, and novel molecular and subcellular mediators of immune dysfunction such as extracellular vesicles, and regenerative medicine approaches such as microglial repopulation.

Shpargel, Karl
WEBSITE
EMAIL
PUBLICATIONS

PHD PROGRAM
Genetics & Molecular Biology

RESEARCH INTEREST
Cancer Biology, Developmental Biology, Genetics, Genomics, Organismal Biology

Our laboratory studies the coordination of histone-modifying enzymes in regulating chromatin structure, enhancer activation, and transcription. We utilize mouse genetics and cell culture model systems to study the mechanisms of enhancer activation in neural crest cell epigenetics, craniofacial development, and altered enhancer regulation in cancer. This is accomplished through a variety of techniques including mouse mutagenesis, fluorescent reporters to isolate primary cells of interest, low cell number genomics, and proteomic approaches.

Milner, Justin
WEBSITE
EMAIL
PUBLICATIONS

PHD PROGRAM
Cell Biology & Physiology, Genetics & Molecular Biology, Microbiology & Immunology, Pharmacology

RESEARCH INTEREST
Cancer Biology, Computational Biology, Genomics, Immunology, Pathogenesis & Infection, Translational Medicine

The overall focus of our lab is to develop new and exciting approaches for enhancing the efficacy of cancer immunotherapies. We utilize cutting-edge techniques to identify transcriptional and epigenetic regulators controlling T cell differentiation and function in the tumor microenvironment, and we seek to leverage this insight to reprogram or tailor the activity of T cells in cancer. Our group is also interested in understanding how to harness or manipulate T cell function to improve vaccines and immunotherapies for acute and chronic infections.

Bowser, Jessica

EMAIL
PUBLICATIONS

PHD PROGRAM
Cell Biology & Physiology, Pathobiology & Translational Science

RESEARCH INTEREST
Biochemistry, Cancer Biology, Cell Biology, Molecular Biology, Translational Medicine

We are studying tissue integrity and repair to develop innovative approaches for regenerative medicine and cancer prevention. We concentrate on highly regenerative (endometrial and intestinal) tissues and are particularly interested in how persistent inflammation influences the breakdown of biochemical pathways that oversee genome stability, stem cell plasticity, and cell adhesions and how these events influence future tissue repair and onset of disease, such as cancer. Projects employ a variety of molecular, cellular, biochemical, genetic, and machine learning techniques that span across cell culture systems, genetically engineered mouse models, and human tissues to understand the impact of acute and chronic inflammation on cell division, cytoskeletal dynamics, and DNA repair in regenerating epithelial cells.

Bryant, Kirsten
WEBSITE
EMAIL
PUBLICATIONS

PHD PROGRAM
Pharmacology

RESEARCH INTEREST
Cancer Biology, Cell Signaling, Metabolism, Pharmacology, Translational Medicine

The overall goal of our lab is to perform research that contributes to a better understanding of pancreatic cancer biology and leads to improved treatments for this disease. One major focus of our studies is the metabolic activity, autophagy, which is a self-degradation process whereby cells can orderly clear defective organelles and recycle macromolecules as a nutrient source. Current projects are focused on further advancing autophagy inhibition as an anti-RAS therapeutic approach, as well as delineating other metabolic consequences of RAF-MEK-ERK MAPK inhibition.

Gladden, Andrew
WEBSITE
EMAIL
PUBLICATIONS

PHD PROGRAM
Pathobiology & Translational Science

RESEARCH INTEREST
Cancer Biology, Cell Biology, Cell Signaling, Developmental Biology, Genetics, Translational Medicine

The Gladden lab studies how cell adhesion and cell polarity are intertwined in normal tissue development and how these pathways are altered in diseases such as cancer. We use a combination of 3D cell culture, mouse models and protein biochemistry to study how cell polarity and adhesion regulate tissue organization. Our work focuses on the interplay between cell adhesion and cell polarity proteins at the adherens junction and how these proteins regulate tissue organization. We concentrate on the development of the endometrium epithelium in the female reproductive tract and the cell biology of endometrial cancer.

Broaddus, Russell
WEBSITE
EMAIL
PUBLICATIONS

PHD PROGRAM
Pathobiology & Translational Science

RESEARCH INTEREST
Cancer Biology, Cell Biology, Molecular Medicine, Pathology, Translational Medicine

My research lab focuses on the molecular pathogenesis of endometrial cancer, the most common gynecologic cancer in the Western world. Current projects include developing molecular diagnostics for predicting endometrial cancer histotype, stage, and recurrence; developing clinical and lab-based algorithms for the identification of patients with hereditary endometrial cancer (Lynch Syndrome); discovering novel molecular mediators of endometrial cancer invasion and metastasis; identifying signaling pathways important in the pathogenesis of endometrial cancer; and identifying molecular determinants of health disparities in endometrial cancer.

Palmer, Adam
WEBSITE
EMAIL
PUBLICATIONS

PHD PROGRAM
Pharmacology

RESEARCH INTEREST
Cancer Biology, Computational Biology, Pharmacology, Systems Biology, Translational Medicine

The Palmer lab investigates combination cancer therapy: understanding the mechanisms of successful drug combinations to inform the development of combinations with new cancer therapies. Our approach is a synthesis of experiments, analysis of clinical data, and modeling. Students can pursue projects that are experimental, computational, or a mixture of both. Our goals are to improve the design of drug combinations, the interpretation of clinical trials, and patient stratification to increase rates of response and cure through more precise use of cancer medicines in combinations.